<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), reportable to US <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registries for diagnoses since 2001, are a group of myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> in prognosis and treatment, and of growing importance in an aging population </plain></SENT>
<SENT sid="1" pm="."><plain>In US registries that have reported incident <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases by subgroup, about 50%-67% of cases have been coded as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> "not otherwise specified" (NOS) in the International Classification of Diseases for <z:hpo ids='HP_0002664'>Oncology</z:hpo> Version 3 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-O-3) </plain></SENT>
<SENT sid="2" pm="."><plain>For this study, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases diagnosed in 2001-2009 and reported to the population-based Connecticut <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> Registry (CTR) were analyzed </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was coded as NOS for 573 (56.7%) of 1,011 cases, but the proportion varied among reporting facilities hospitals (ie, from 0 to 100%), with several statistical outliers </plain></SENT>
<SENT sid="4" pm="."><plain>In pathology reports obtained for 130 CTR patients diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in 2008-2009, 84% of the 62 patients coded as NOS had information on a key element (ie, % of blasts in bone marrow) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-O-3 coding and other classifications of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subgroups </plain></SENT>
<SENT sid="5" pm="."><plain>These findings suggest that central <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registries may want to work with hospital <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> registrars in improving reporting of specific <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subgroups using <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-O-3 </plain></SENT>
<SENT sid="6" pm="."><plain>The addition of % blasts from pathology reports to the site-specific factors for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in the Collaborative Staging System could be proposed </plain></SENT>
</text></document>